Umecrine Mood AB’s business concept is to develop treatments for the negative mental and physical symptoms in PMDD/PMS caused by endogenous CNS-active steroids (GABA-steroids) derived from the corpus luteum of the ovary. The company offers a unique and novel treatment principle based on modulation of GABA-steroid action.
The company strategy is to demonstrate proof-of-concept for the treatment of PMDD/PMS, and while continuing the development seek a strategic partnership or an M&A transaction with a company searching for a new opportunity within the field of CNS or Women’s Health.